… The present study was performed to elucidate the pharmacokinetic behaviour of midazolam
following intravenous and oral dose administration and to calculate its bioavailability. …

… that the oral bioavailability of midazolam was 66% (25–85%). While the systemic exposure
to OHM and OHMG decreased with increasing age, the systemic exposure to midazolam …

… Incomplete oral absorption of midazolam is also not likely to be a determinant because the
… of the major metabolite, 1’-hydroxy midazolam, was similar after both intravenous and oral …

… and oral microgram and milligram doses of midazolam to evaluate the linearity of bioavailability
… This study shows linearity of absorption, distribution, metabolism and elimination of a …

… nearly complete absorption across the intestinal lumen after oral administration, a short
plasma half-life, and little or no side effects after a subtherapeutic dose), l&l7 makes midazolam a …

… midazolam disposition following oral administration in preterm infants are lacking. Midazolam
undergoes extensive metabolism … AUC(0,t) ratio is substantially lower and bioavailability …

… The main purpose of this study was to determine the absolute bioavailability of subcutaneous
midazolam. In the absence of relevant pharmacokinetic data on midazolam given …

… of midazolam because of its … absorption of midazolam at low doses (15 and 50 μg/kg) in the
present study, possibly leading to reduced bioavailability compared with the bioavailability at …

… maximal bioavailability increase as 16 seconds. In conclusion, midazolam bioavailability is
… of buccal exposure will increase bioavailability due to buccal absorption. This needs to be …

… The inherent variability in midazolam bioavailability and metabolism underscores the … of
midazolam and its primary metabolite, α-hydroxymidazolam, after IV administration and after oral …